Author name: TB Alliance

JOHANNESBURG, 4 Jan 2005 (IRIN) – In the crowded wards of African hospitals, coughs and bony bodies tell the story

Scientists are making progress on TB—again. For a disease that scientists conquered 40 years ago, tuberculosis has made an astonishing

The Stop TB Partnership Working Group on TB Drug Development held its annual meeting on October 29, 2004. Led by

At the 2004 annual meeting, the Stakeholders reviewed highlights of the TB Alliance’s portfolio advances and its policy and outreach

The TB Alliance’s mission – to shorten and improve TB treatment – will ultimately rest on designing a new regimen

The first promising tuberculosis (TB) drug in almost 40 years could be the most potent yet and also treat the

Scientists believe they have found a tuberculosis (TB) drug that could succeed where others are failing. Although it is still

A chief reason that tuberculosis persists as a global killer–and is on the rise in parts of the world–is that

The TB Alliance is pleased to welcome Johnson & Johnson to the select group of companies and organizations working diligently

Next generation of drugs perform well against resistant strains. Tuberculosis kills 2 million people a year, but a promising drug